Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Measuring sympathetic skin response or heart rate variability can provide an objective
biomarker of bladder sensation and its modulation by drug with potential to treat overactive
bladder.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.